sur CROSSJECT (EPA:ALCJ)
Crossject: Update on voting rights and shares as of January 31, 2025
The pharmaceutical company CROSSJECT, specializing in the development of drugs for emergencies, published in Dijon on March 10, 2025 an update concerning the total number of voting rights and shares as of January 31, 2025. This publication complies with the requirements of Articles 223-16 of the AMF General Regulations and L.233-8 II of the French Commercial Code.
As of February 28, 2025, CROSSJECT had 45,539,227 shares comprising its share capital. The number of theoretical voting rights amounted to 55,492,332, while the exercisable voting rights were slightly lower, amounting to 55,352,017, due to 123,310 shares deprived of voting rights.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CROSSJECT